SURG vs STXS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

SURG

37.8
AI Score
VS
SURG Wins

STXS

32.7
AI Score

Investment Advisor Scores

SURG

38score
Recommendation
AVOID NEW MONEY

STXS

33score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric SURG STXS Winner
Forward P/E 16.4474 19.6464 SURG
PEG Ratio 0.5333 1.3109 SURG
Revenue Growth 40.7% -12.8% SURG
Earnings Growth -77.7% 0.0% STXS
Tradestie Score 37.8/100 32.7/100 SURG
Profit Margin -47.9% -74.2% SURG
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY AVOID NEW MONEY Tie

Relative Price Performance (Last 90 Days)

SURG 1M: +18.0% · 3M: -38.9% STXS 1M: -18.0% · 3M: -37.0%

Current Technical Phase

SURG

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 50.2 · Price: $0.15

STXS

Markdown
Sell / avoid

Price below a falling SMA50 (slope -12.9%), weak momentum, RSI 38

RSI (14): 37.8 · Price: $0.87

Fundamentals Snapshot

Metric SURG STXS
Market Cap — —
Forward P/E 15.8 -6.7
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.4% -0.1%
Gross Margin -0.2% 0.6%
Operating Margin 0.2% -0.6%
EPS -1.50 -0.24
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, SURG is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.